Moreover, based on data from The Cancer Genome Atlas (TCGA), ASS1 loss confers significantly reduced 5‐year survival rates (25% “low” vs. 44% “high” ASS1 expression; p = 0.007; n = 500) for all stages of lung adenocarcinoma, including patients in adjuvant and metastatic treatment settings.15 The gene discussed is ASS1; the disease is lung adenocarcinoma.